Senior Living - SeniorCenters.com

Senior Living

Senior Living
Prostate / Prostate Cancer News From Medical News Today
Latest Prostate / Prostate Cancer News From Medical News Today.
Institute Scientist Receives Global Award To Aid The Fight Against Prostate Cancer The Institute of Cancer Research's scientist, Dr Gerhardt Attard has just been awarded a Young Investigator Award by the Prostate Cancer Foundation (PCF) for his ongoing work into developing the prostate cancer drug abiraterone. Designed to encourage the most innovative research thinkers to continue their careers in prostate cancer research, the awards provide recipients with $75,000 annually for three years to support specified research programs. Obese Prostate Cancer Patients May Benefit More From Brachytherapy Brachytherapy, also called seed implants, may be a more beneficial treatment than surgery or external beam radiation therapy for overweight or obese prostate cancer patients, according to a study published in the August issue of the International Journal of Radiation OncologyBiologyPhysics, the official journal of the American Society for Therapeutic Radiology and Oncology. Total And Free PSA (PSA/fPSA) Assays Now Available For The Olympus AU3000i Immunoassay Analyser Olympus is pleased to announce the launch of highly sensitive and precise PSA (Prostate Specific Antigen) and fPSA assays for the Olympus AU3000i immunoassay analyser. The use of PSA and fPSA is well established in the screening and management of prostate cancer. Olympus is joining this market with an extremely sensitive PSA assay with a functional sensitivity of 0.015 Âµg/L. Tadalafil Shows Promise For Relief Of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of tadalafil (Cxxxxs®) to relieve associated lower urinary tract symptoms (LUTS), according to a new study published in the October 2008 issue of The Journal of Urology. Synthetic Molecules Could Add Spice To Fight Against Cancer Seeking to improve on nature, scientists used a spice-based compound as a starting point and developed synthetic molecules that, in lab settings, are able to kill cancer cells and stop the cells from spreading. The researchers are combining organic chemistry, computer-aided design and molecular biology techniques in developing and testing pharmaceutical compounds that can fight breast and prostate cancer cells. Evidence Of Activity Seen In New Data From ASA404 Prostate Cancer Trial Antisoma plc (LSE: ASM; USOTC: ATSMY) announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone. The hazard ratio expressing the relative risk of death in the ASA404 and control groups favoured the ASA404 group (hazard ratio 0.8; 95% confidence intervals 0.46-1.39). Alternative Vaccine Strategy Shows Promise In Prostate Cancer Patients New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients. This study, led by researchers at that National Cancer Institute (NCI), part of the National Institutes of Health, was published in the Aug. Consistent PSA Screening Results In Better Prognosis Recently, PSA or prostate-specific antigen, screening made headlines when a US Preventive Task Force recommended that men over the age 75 discontinue screening for prostate cancer. The Influence Of Serial Prostate-Specific Antigen (PSA) Screening On The PSA Velocity At Diagnosis UroToday.com - The PSA test is now a widely used test for screening men for prostate cancer in the United States. Since it was first introduced more than 20 years ago, the most common presentation of a man with newly diagnosed prostate cancer has changed dramatically. Compared to the era before PSA, he is younger, has less aggressive cancer, and his tumor stage is more favorable. Alternative Nonsteroidal Antiandrogen Therapy For Advanced Prostate Cancer That Relapsed After Initial Maximum Androgen Blockade UroToday.com - In the September, 2008 issue of the Journal of Urology, Dr. Hiroyoshi Suzuki and Japanese collaborators reported that following maximum androgen blockade (MAB) for prostate cancer (CaP), the use of alternative nonsteroidal antiandrogens is effective for treating relapsed disease. A total of 232 CaP patients treated with MAB and disease progression made up the study cohort. Upon disease relapse they were treated with an alternative antiandrogen.

[ Back ]